KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Share-based Compensation (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Share-based Compensation data on record, last reported at $13.2 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 26.65% year-over-year to $13.2 million; the TTM value through Dec 2025 reached $52.1 million, down 22.24%, while the annual FY2025 figure was $52.1 million, 22.24% down from the prior year.
  • Share-based Compensation reached $13.2 million in Q4 2025 per ACAD's latest filing, roughly flat from $13.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $26.2 million in Q3 2024 and bottomed at $10.4 million in Q4 2024.
  • Average Share-based Compensation over 5 years is $15.9 million, with a median of $14.9 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: skyrocketed 41.13% in 2024, then plummeted 49.63% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $12.9 million in 2021, then increased by 11.91% to $14.4 million in 2022, then grew by 25.04% to $18.0 million in 2023, then tumbled by 42.02% to $10.4 million in 2024, then rose by 26.65% to $13.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $13.2 million in Q4 2025, $13.2 million in Q3 2025, and $14.3 million in Q2 2025.